Consolidated Statements of Shareholders' Equity - USD ($)
Total
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series E Convertible Preferred Stock [Member]
Common Stock [Member]
Capital in Excess of Par Value [Member]
Treasury Stock [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Beginning balance at Dec. 31, 2012 $ 31,365,000     $ 109,000 $ 279,464,000 $ (125,000) $ (248,366,000) $ 283,000
Beginning balance, shares at Dec. 31, 2012     23,000 10,943,000   (5,000)    
Options exercised and restricted shares vested 11,000     $ 1,000 11,000      
Options exercised and restricted shares vested, shares       27,000        
Issuance of common stock in connection with the acquisition of Juniper Pharma Services 7,295,000     $ 11,000 7,284,000      
Issuance of common stock in connection with the acquisition of Juniper Pharma Services, shares       1,051,000        
Conversion of series E preferred stock       $ 1,000 (157,000) $ 156,000    
Conversion of series E preferred stock, shares     (23,000) 131,000   11,000    
Purchase of treasury stock (31,000)         $ (31,000)    
Purchase of treasury stock, shares           (6,000)    
Share based compensation expense $ 476,000       $ 475,000      
Share based compensation expense, shares 0 0 0 0 0 0 0 0
Dividends on preferred stock $ (28,000)       $ (28,000)      
Reverse stock split - cash in lieu (1,000)       (1,000)      
Translation adjustment 1,184,000             $ 1,184,000
Unrealized loss on short term investments (80,000)             (80,000)
Reclassification adjustment for gains included in net income (17,000)             (17,000)
Net (loss) income 6,704,000           $ 6,704,000  
Ending balance at Dec. 31, 2013 46,878,000     $ 122,000 287,048,000   $ (241,662,000) $ 1,370,000
Ending balance, shares at Dec. 31, 2013       12,152,000        
Options exercised and restricted shares vested 33,000       33,000      
Options exercised and restricted shares vested, shares       34,000        
Purchase of treasury stock (8,579,000)         $ (8,579,000)    
Purchase of treasury stock, shares           (1,411,000)    
Share based compensation expense $ 607,000       $ 607,000      
Share based compensation expense, shares 0 0 0 0 0 0 0 0
Dividends on preferred stock $ (28,000)       $ (28,000)      
Translation adjustment (1,433,000)             $ (1,433,000)
Net (loss) income 3,390,000           $ 3,390,000  
Ending balance at Dec. 31, 2014 40,868,000     $ 122,000 287,660,000 $ (8,579,000) $ (238,272,000) $ (63,000)
Ending balance, shares at Dec. 31, 2014       12,186,000   (1,411,000)    
Options exercised and restricted shares vested 60,000       82,000 $ (22,000)    
Options exercised and restricted shares vested, shares       29,000   (2,000)    
Share based compensation expense $ 1,750,000       $ 1,750,000      
Share based compensation expense, shares 0 0 0 0 0 0 0 0
Dividends on preferred stock $ (28,000)       $ (28,000)      
Translation adjustment (1,099,000)             $ (1,099,000)
Net (loss) income (2,134,000)           $ (2,134,000)  
Ending balance at Dec. 31, 2015 $ 39,417,000     $ 122,000 $ 289,464,000 $ (8,601,000) $ (240,406,000) $ (1,162,000)
Ending balance, shares at Dec. 31, 2015       12,215,000   (1,413,000)